110 related articles for article (PubMed ID: 8360492)
21. Modulation of pulmonary macrophage superoxide release and tumoricidal activity following activation by biological response modifiers.
Drath DB
Immunopharmacology; 1986 Oct; 12(2):117-26. PubMed ID: 3021650
[TBL] [Abstract][Full Text] [Related]
22. Liposome encapsulation of muramyl peptides for activation of macrophage cytotoxic properties.
Nayar R; Schroit AJ; Fidler IJ
Methods Enzymol; 1986; 132():594-603. PubMed ID: 3547028
[No Abstract] [Full Text] [Related]
23. The induction and augmentation of macrophage tumoricidal responses by platelet-activating factor.
Howard AD; Erickson KL
Cell Immunol; 1995 Aug; 164(1):105-12. PubMed ID: 7634340
[TBL] [Abstract][Full Text] [Related]
24. Taxol provides a second signal for murine macrophage tumoricidal activity.
Manthey CL; Perera PY; Salkowski CA; Vogel SN
J Immunol; 1994 Jan; 152(2):825-31. PubMed ID: 7506736
[TBL] [Abstract][Full Text] [Related]
25. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide.
Kleinerman ES; Erickson KL; Schroit AJ; Fogler WE; Fidler IJ
Cancer Res; 1983 May; 43(5):2010-4. PubMed ID: 6831430
[TBL] [Abstract][Full Text] [Related]
26. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes.
Fidler IJ; Fogler WE; Kleinerman ES; Saiki I
J Immunol; 1985 Dec; 135(6):4289-96. PubMed ID: 3934281
[TBL] [Abstract][Full Text] [Related]
27. Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes.
Daemen T; Veninga A; Dijkstra J; Scherphof G
J Immunol; 1989 Apr; 142(7):2469-74. PubMed ID: 2926140
[TBL] [Abstract][Full Text] [Related]
28. Comparative efficacy of liposomes containing synthetic bacterial cell wall analogues for tumoricidal activation of monocytes and macrophages.
Utsugi T; Nii A; Fan D; Pak CC; Denkins Y; van Hoogevest P; Fidler IJ
Cancer Immunol Immunother; 1991; 33(5):285-92. PubMed ID: 1868486
[TBL] [Abstract][Full Text] [Related]
29. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages.
Fogler WE; Fidler IJ
Cancer Res; 1985 Jan; 45(1):14-8. PubMed ID: 3855280
[TBL] [Abstract][Full Text] [Related]
30. [Antitumoral activation of rat peritoneal macrophages by muramyl dipeptide in vitro].
Reisser D; Jeannin JF; Martin F
C R Seances Acad Sci III; 1982 Nov; 295(8):485-8. PubMed ID: 6819063
[TBL] [Abstract][Full Text] [Related]
31. Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes.
Saiki I; Sone S; Fogler WE; Kleinerman ES; Lopez-Berestein G; Fidler IJ
Cancer Res; 1985 Dec; 45(12 Pt 1):6188-93. PubMed ID: 3933823
[TBL] [Abstract][Full Text] [Related]
32. Induction of macrophage antitumor activity by acetylated low density lipoprotein containing lipophilic muramyl tripeptide.
Shaw JM; Futch WS; Schook LB
Proc Natl Acad Sci U S A; 1988 Aug; 85(16):6112-6. PubMed ID: 3413079
[TBL] [Abstract][Full Text] [Related]
33. In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.
Tanguay S; Bucana CD; Wilson MR; Fidler IJ; von Eschenbach AC; Killion JJ
Cancer Res; 1994 Nov; 54(22):5882-8. PubMed ID: 7954418
[TBL] [Abstract][Full Text] [Related]
34. Monocyte chemotactic and activating factor gene expression induced in endothelial cells by IL-1 and tumor necrosis factor.
Sica A; Wang JM; Colotta F; Dejana E; Mantovani A; Oppenheim JJ; Larsen CG; Zachariae CO; Matsushima K
J Immunol; 1990 Apr; 144(8):3034-8. PubMed ID: 2182712
[TBL] [Abstract][Full Text] [Related]
35. Role of tumor necrosis factor and interleukin 1 in gamma-interferon-promoted activation of mouse tumoricidal macrophages.
Hori K; Mihich E; Ehrke MJ
Cancer Res; 1989 May; 49(10):2606-14. PubMed ID: 2496917
[TBL] [Abstract][Full Text] [Related]
36. Human recombinant macrophage inflammatory protein-1 alpha and -beta and monocyte chemotactic and activating factor utilize common and unique receptors on human monocytes.
Wang JM; Sherry B; Fivash MJ; Kelvin DJ; Oppenheim JJ
J Immunol; 1993 Apr; 150(7):3022-9. PubMed ID: 8454871
[TBL] [Abstract][Full Text] [Related]
37. The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide.
Xu Z; Fidler IJ
Cancer Immunol Immunother; 1984; 18(2):118-22. PubMed ID: 6391654
[TBL] [Abstract][Full Text] [Related]
38. Lack of production of interleukin 1 by human blood monocytes activated to the antitumor state by liposome-encapsulated muramyl tripeptide.
Tandon P; Utsugi T; Sone S
Cancer Res; 1986 Oct; 46(10):5039-44. PubMed ID: 3489519
[TBL] [Abstract][Full Text] [Related]
39. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Sone S; Fidler IJ
J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
[TBL] [Abstract][Full Text] [Related]
40. Activation and priming of human monocytes by monocyte chemotactic activating factor: cooperation with other inflammatory cytokines and close association between an increase in cytoplasmic free Ca2+ and intracellular acidification.
Azuma EK; Yuo A; Matsushima T; Kasahara T; Mizoguchi H; Saito M; Takaku F; Kitagawa S
Exp Hematol; 1996 Feb; 24(2):169-75. PubMed ID: 8641338
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
